{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:04Z","timestamp":1791335644437,"version":"4.3.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamaoncol.2018.5428","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T11:34:04Z","timestamp":1546515244000},"page":"351","source":"Crossref","is-referenced-by-count":140,"title":["Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma"],"prefix":"10.1001","volume":"5","author":[{"given":"Raffit","family":"Hassan","sequence":"first","affiliation":[{"name":"Thoracic and GI Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Nemunaitis","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Toledo College of Medicine, Toledo, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Thoracic Oncology Unit, University Hospital of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin L.","family":"Chen","sequence":"additional","affiliation":[{"name":"Novant Health Oncology Specialists, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samith T.","family":"Kochuparambil","sequence":"additional","affiliation":[{"name":"Virginia Piper Cancer Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Powderly","sequence":"additional","affiliation":[{"name":"Carolina BioOncology Institute, Huntersville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka N.","family":"Vaishampayan","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Juergen","family":"Grote","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"von Heydebreck","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chin","sequence":"additional","affiliation":[{"name":"EMD Serono, Billerica, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi180097r1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/(ISSN)1097-0274","article-title":"The global burden of disease due to occupational carcinogens.","volume":"48","author":"Driscoll","year":"2005","journal-title":"Am J Ind Med"},{"key":"coi180097r2","doi-asserted-by":"publisher","first-page":"2782590","DOI":"10.1155\/2017\/2782590","article-title":"Life expectancy in pleural and peritoneal mesothelioma.","volume":"2017","author":"Shavelle","year":"2017","journal-title":"Lung Cancer Int"},{"issue":"10","key":"coi180097r3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","article-title":"Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.","volume":"2","author":"Flores","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"14","key":"coi180097r5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180097r6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"issue":"1","key":"coi180097r7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.","volume":"109","author":"Fennell","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"coi180097r8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.","volume":"1","author":"J\u00e4nne","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"8","key":"coi180097r9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/(ISSN)1097-0142","article-title":"A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.","volume":"112","author":"Okuno","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"coi180097r10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"issue":"3","key":"coi180097r11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"issue":"7","key":"coi180097r12","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"coi180097r13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"coi180097r14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)\u2013Medicare investigation of treatment patterns and overall survival.","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"5","key":"coi180097r15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions.","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"coi180097r16","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti\u2013PD-L1 antibody avelumab.","volume":"11","author":"Khanna","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"5","key":"coi180097r17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma.","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"7","key":"coi180097r18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"5","key":"coi180097r19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"coi180097r20","doi-asserted-by":"publisher","first-page":"abstract LBA58_PR","DOI":"10.1093\/annonc\/mdx440.074","article-title":"Second or 3rd line nivolumab (Nivo) versus Nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial","volume":"28","author":"Zalcman","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"coi180097r21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi180097r22","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti\u2013PD-L1 antibody avelumab (MSB0010718C) on human tumor cells.","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"coi180097r25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"coi180097r26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti\u2013programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study.","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi180097r27","doi-asserted-by":"publisher","first-page":"abstract 4009","DOI":"10.1200\/JCO.2016.34.15_suppl.4009","article-title":"Avelumab (MSB0010718C; anti\u2013PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN Solid Tumor phase Ib trial: analysis of safety and clinical activity","volume":"34","author":"Chung","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi180097r28","doi-asserted-by":"publisher","first-page":"abstract 5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti\u2013PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi180097r29","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"coi180097r32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"2","key":"coi180097r33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi180097r34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time.","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"coi180097r23","year":"2017"},{"key":"coi180097r24","year":"2017"},{"key":"coi180097r30","volume-title":"ICH Harmonised Guideline: Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6(R2)","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2016"},{"key":"coi180097r4","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: malignant pleural mesothelioma. V2. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf. Accessed June 5, 2018."},{"key":"coi180097r31","unstructured":"National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published June 14, 2010. Accessed June 5, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/3\/351\/17345755\/jamaoncology_hassan_2019_oi_180097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T11:30:52Z","timestamp":1552563052000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.5428"}},"subtitle":["Phase 1b Results From the JAVELIN Solid Tumor Trial"],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.5428","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}